Cargando…

Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy

Myotonic Dystrophy type 1 (DM1) is a neuromuscular disease associated with toxic RNA containing expanded CUG repeats. The developing therapeutic approaches to DM1 target mutant RNA or correct early toxic events downstream of the mutant RNA. We have previously described the benefits of the correction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lutz, Maggie, Levanti, Miranda, Karns, Rebekah, Gourdon, Genevieve, Lindquist, Diana, Timchenko, Nikolai A., Timchenko, Lubov
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342152/ https://www.ncbi.nlm.nih.gov/pubmed/37445828 http://dx.doi.org/10.3390/ijms241310650

Ejemplares similares

Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
por: Timchenko, Lubov
Publicado: (2019)

GSK3β is a new therapeutic target for myotonic dystrophy type 1
por: Wei, Christina, et al.
Publicado: (2013)

Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022)

Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022)

Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010)

GSK3β and aging liver
por: Jin, Jingling, et al.
Publicado: (2009)

Smaug/SAMD4A Restores Translational Activity of CUGBP1 and Suppresses CUG-Induced Myopathy
por: de Haro, Maria, et al.
Publicado: (2013)

Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS
por: Gourdon, Genevieve, et al.
Publicado: (2017)

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2
por: Cardani, Rosanna, et al.
Publicado: (2013)

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease
por: Cast, Ashley, et al.
Publicado: (2019)

Phosphorylation-Mediated Activation of β-Catenin-TCF4-CEGRs/ALCDs Pathway Is an Essential Event in Development of Aggressive Hepatoblastoma
por: Gulati, Ruhi, et al.
Publicado: (2022)

Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy
por: Braz, Sandra O., et al.
Publicado: (2018)

Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial
por: Kurkiewicz, Adam, et al.
Publicado: (2020)

PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma
por: Valanejad, Leila, et al.
Publicado: (2018)

Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing
por: Hernández-Hernández, Oscar, et al.
Publicado: (2013)

Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy
por: Panaite, Petrica-Adrian, et al.
Publicado: (2013)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Electrophysiological basis of cardiac arrhythmia in a mouse model of myotonic dystrophy type 1
por: Ginjupalli, Vamsi Krishna Murthy, et al.
Publicado: (2023)

β‐catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma
por: Gulati, Ruhi, et al.
Publicado: (2022)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
por: Ait Benichou, Siham, et al.
Publicado: (2022)

Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPα-p300 Axis
por: Nguyen, Phuong, et al.
Publicado: (2018)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma
por: Timchenko, Nikolai A
Publicado: (2015)

Help for Sick Kids: New Insights Into Hepatoblastoma
por: Timchenko, Nikolai A.
Publicado: (2021)

Quantitative Measurement of GLUT4 Translocation to the Plasma Membrane by Flow Cytometry
por: Koshy, Shyny, et al.
Publicado: (2010)

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
por: Jauvin, Dominic, et al.
Publicado: (2017)

Desflurane anaesthesia in myotonic dystrophy
por: Gandhi, Ranju, et al.
Publicado: (2011)

Myotonic Dystrophy: An Anaesthetic Dilemma
por: Gupta, N, et al.
Publicado: (2009)

Cardiac involvement in myotonic dystrophy
por: Khalighi, Koroush, et al.
Publicado: (2015)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Cutaneous findings in myotonic dystrophy
por: Kong, Ha Eun, et al.
Publicado: (2022)

Excessive rest time during active phase is reliably detected in a mouse model of myotonic dystrophy type 1 using home cage monitoring
por: Golini, Elisabetta, et al.
Publicado: (2023)

Robust Detection of Somatic Mosaicism and Repeat Interruptions by Long-Read Targeted Sequencing in Myotonic Dystrophy Type 1
por: Mangin, Antoine, et al.
Publicado: (2021)

Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes
por: Dincã, Diana M., et al.
Publicado: (2022)

Straightjacket/α2δ3 deregulation is associated with cardiac conduction defects in myotonic dystrophy type 1
por: Auxerre-Plantié, Emilie, et al.
Publicado: (2019)

CRISPR/Cas9-Induced (CTG⋅CAG)(n) Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing
por: van Agtmaal, Ellen L., et al.
Publicado: (2017)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Downregulation of the Glial GLT1 Glutamate Transporter and Purkinje Cell Dysfunction in a Mouse Model of Myotonic Dystrophy
por: Sicot, Géraldine, et al.
Publicado: (2017)

Molecular signatures of aggressive pediatric liver cancer
por: Johnston, Michael E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_94tv14jqkefpr0taoeva27g2dk